VYNE Therapeutics Inc. Quarterly Share-based Payment Arrangement, Expense in USD from Q1 2017 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
VYNE Therapeutics Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q1 2017 to Q2 2024.
  • VYNE Therapeutics Inc. Share-based Payment Arrangement, Expense for the quarter ending June 30, 2024 was $885K, a 1.03% increase year-over-year.
  • VYNE Therapeutics Inc. Share-based Payment Arrangement, Expense for the twelve months ending June 30, 2024 was $3.44M, a 13.3% decline year-over-year.
  • VYNE Therapeutics Inc. annual Share-based Payment Arrangement, Expense for 2023 was $3.31M, a 23.1% decline from 2022.
  • VYNE Therapeutics Inc. annual Share-based Payment Arrangement, Expense for 2022 was $4.3M, a 46.8% decline from 2021.
  • VYNE Therapeutics Inc. annual Share-based Payment Arrangement, Expense for 2021 was $8.08M.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 $3.44M $885K +$9K +1.03% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-14
Q1 2024 $3.43M $985K +$129K +15.1% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-09
Q4 2023 $3.31M $710K -$357K -33.5% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-01
Q3 2023 $3.66M $863K -$311K -26.5% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-13
Q2 2023 $3.97M $876K -$287K -24.7% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-14
Q1 2023 $4.26M $856K -$37K -4.14% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-09
Q4 2022 $4.3M $1.07M -$265K -19.9% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-01
Q3 2022 $4.56M $1.17M -$1.23M -51.2% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-13
Q2 2022 $5.79M $1.16M -$738K -38.8% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-14
Q1 2022 $6.53M $893K -$1.55M -63.4% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-11
Q4 2021 $8.08M $1.33M Oct 1, 2021 Dec 31, 2021 10-K 2023-03-14
Q3 2021 $2.41M -$215K -8.21% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-14
Q2 2021 $1.9M -$8.87M -82.3% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-12
Q1 2021 $2.44M +$683K +38.8% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-12
Q3 2020 $18.2M $2.62M +$1.35M +106% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-10
Q2 2020 $16.8M $10.8M +$9.38M +676% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-12
Q1 2020 $7.44M $1.76M +$740K +72.6% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-06
Q4 2019 $6.7M $3.03M +$4.89M Oct 1, 2019 Dec 31, 2019 10-K 2020-03-03
Q3 2019 $1.81M $1.27M +$275K +27.7% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-05
Q2 2019 $1.54M $1.39M +$642K +86.1% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-06
Q1 2019 $897K $1.02M +$197K +24% Jan 1, 2019 Mar 31, 2019 10-Q 2019-05-02
Q4 2018 $700K -$1.86M -$2.1M -892% Oct 1, 2018 Dec 31, 2018 10-K 2021-03-04
Q3 2018 $2.8M $994K +$405K +68.8% Jul 1, 2018 Sep 30, 2018 10-Q 2019-10-31
Q2 2018 $2.39M $746K +$434K +139% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-01
Q1 2018 $1.96M $822K +$506K +160% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-02
Q4 2017 $1.45M $235K Oct 1, 2017 Dec 31, 2017 10-K 2020-03-03
Q3 2017 $589K Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-07
Q2 2017 $312K Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-01
Q1 2017 $316K Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-09
* An asterisk sign (*) next to the value indicates that the value is likely invalid.